Coronavirus disease 2019 (COVID‐19) has rapidly spread worldwide, posing a serious public health problem.¹ The prevalence of asthma in COVID‐19 patents differs among studies, with 0.0% reported in Wuhan, China, and markedly higher prevalence rates of 17% and 14% reported in the United States (US) and the United Kingdom (UK), respectively.^2–4 Data from the UK showed that asthma was a risk factor for severe COVID‐19; however, another study from the United States showed no association between asthma and severe disease, suggesting that it is still unclear whether asthma is a risk factor for a poor prognosis.